• If you are wondering whether Kenvue's current share price offers value, or if you are better off waiting on the sidelines, this article breaks down what the market is pricing in and how that compares with several valuation checks.
• The stock recently closed at US$16.88 and has fallen 4.3% over the last week, 2.8% over the last month, and 2.5% year to date. The return over the past year is down 18.4% and down 24.1% over three years.
• Recent news flow around Kenvue has focused on its position as a standalone consumer health company and ongoing interest in how it is balancing growth investments with returns to shareholders. This backdrop helps explain why some investors are reassessing both the risks and the potential rewards at the current share price.
• Kenvue currently has a valuation score of 3 out of 6. The rest of this article will unpack what that means across different valuation approaches, and will also point to a more complete way to think about valuation that will be highlighted at the end.

Approach 1: Kenvue Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value using a required return.

For Kenvue, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $1.77b. Analyst estimates and subsequent extrapolations point to free cash flow of $2.18b in 2026, rising to a projected $2.83b in 2030. The later years are based on Simply Wall St’s extrapolations once analyst coverage tapers off.

After discounting these projected cash flows, the DCF model arrives at an estimated intrinsic value of about $29.80 per share. Compared with the recent share price of $16.88, this implies the stock is trading at a 43.4% discount to this DCF estimate. This points to Kenvue being undervalued on this specific cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Kenvue is undervalued by 43.4%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: Kenvue Price vs Earnings

For profitable companies, the P/E ratio is a widely used gauge because it links what you pay for the stock to the earnings the business is currently generating. Investors generally accept paying a higher P/E when they expect stronger growth or see lower risk, and a lower P/E when growth expectations are weaker or risks are higher.

Kenvue currently trades on a P/E of 19.98x. That sits above the Personal Products industry average P/E of 17.96x, yet below the broader peer group average of 36.08x. Simply comparing to peers or the industry can be misleading because it ignores company specific factors such as earnings growth profile, profit margins, size and risk.

To handle that, Simply Wall St uses a proprietary “Fair Ratio” that estimates what a reasonable P/E might be for Kenvue after accounting for its earnings growth characteristics, industry, margins, market cap and risk profile. For Kenvue, this Fair Ratio is 18.83x. Since the current P/E of 19.98x is modestly above this Fair Ratio, the stock screens as slightly overvalued on this earnings multiple view.

Result: OVERVALUED

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Upgrade Your Decision Making: Choose your Kenvue Narrative

Earlier it was mentioned that there is an even better way to think about valuation, and on Simply Wall St this is done through Narratives, where you spell out your story for Kenvue, link it to assumptions for revenue, earnings and margins, and the platform turns that into a forecast and a Fair Value that you can compare with the current price to help decide whether to act or wait. Each Narrative sits on the Community page and updates automatically when new earnings or news arrive. A more optimistic investor might lean toward the higher analyst target of US$23.00, while a more cautious investor might anchor closer to US$18.00, yet both are using the same tool to connect their view of Kenvue’s future to numbers.

Do you think there's more to the story for Kenvue? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.